Carterra

About Carterra

Carterra is a biotechnology company revolutionizing antibody discovery and characterization through its high-throughput surface plasmon resonance (HT-SPR™) technology. Headquartered in the United States, Carterra develops and manufactures powerful analytical instruments that enable pharmaceutical and biotech companies to accelerate therapeutic discovery, particularly in antibody and small molecule drug development.

At the heart of Carterra’s offering is its proprietary HT-SPR™ platform, with instruments like the Carterra LSA, LSA XT, and Ultra, which allow researchers to rapidly generate high-resolution data on antibody kinetics, binding affinities, and epitope diversity—all while using only a fraction of the sample volume typically required. These instruments allow simultaneous screening and in-depth characterization of hundreds of antibody interactions in a single run, drastically reducing the time and cost of the drug discovery process.

Carterra’s technology is widely adopted by leading pharmaceutical companies, research institutions, and biotech firms seeking to make data-driven decisions at the earliest stages of therapeutic development. Their platforms are used for a range of applications including epitope binning, antibody affinity profiling, fragment screening, and characterization of difficult targets such as GPCRs and kinases.

The company’s technology played a critical role in the development of Eli Lilly’s COVID-19 therapeutic, demonstrating the real-world impact and scalability of its high-throughput capabilities. With integrated AI and machine learning tools, Carterra is also helping researchers unlock deeper insights from complex biological data, enabling a new era of precision in drug development.

By offering unmatched throughput, resolution, and efficiency, Carterra is setting a new standard in biologics discovery and helping to bring life-saving therapies to market faster.